Science

Viagra-family drug slows Alzheimer's decline by 31 percent in late-stage trial

AriBio's AR1001 raises blood flow to the brain rather than clearing amyloid, benefit held only in patients taking no other treatment

Images

Drug that mimics Viagra shows promise as Alzheimer's treatment Drug that mimics Viagra shows promise as Alzheimer's treatment euronews.com

A once-daily tablet from the same drug family as Viagra slowed cognitive decline by 31% in people with early Alzheimer's disease, according to results presented at the Clinical Trials on Alzheimer's Disease conference in the United States. The late-stage trial, run by the South Korean company AriBio, followed 604 patients across 13 countries.

AR1001 belongs to the class of drugs called PDE5 inhibitors, the family that made Viagra famous, and its mechanism is unglamorous: it relaxes blood vessels to increase blood flow to the brain. For a field whose recent approvals have centred on antibody infusions designed to clear amyloid from the brain, a small tablet working on the organ's blood supply is a pointed contrast. Richard Oakley, associate director for research and innovation at the Alzheimer's Society, called the topline results "an exciting sign that we could have a totally new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms."

The headline number carries the caveat that will decide the drug's fate. The 31% slowing of cognitive decline and memory loss appeared among patients with early disease who were taking no other treatment; in the wider group of patients already on other drugs, AriBio itself reports the result fell short of statistical significance. Side effects were mostly mild to moderate, including diarrhoea, falls and dizziness.

Dementia affects 57 million people worldwide, and there is no cure for Alzheimer's, its most common form. That absence is why treatments that slow the disease rather than reverse it remain the field's whole ambition, and why experts greeted the AR1001 numbers as encouraging while insisting more research is needed before the drug reaches patients. AriBio says it plans to discuss the findings with the US Food and Drug Administration.

Oakley's remaining advice was addressed to anyone tempted to improvise in the meantime: AR1001 comes from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer's disease.